Meeting
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
Authors
Patrick McKay Boland
Roswell Park Cancer Institute, Buffalo, NY
Patrick McKay Boland , Marwan Fakih , Kristopher Attwood , Melissa Robins , Renuka V. Iyer , Wen Wee Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02393755
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 759)
DOI
10.1200/JCO.2017.35.4_suppl.759
Abstract #
759
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter study.
First Author: Jiwon Lee
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando